CART19-BE-02 trial: From Bench to Bedside and Beyond – Resonance

oncodaily - ALRCaN presents “CART19-BE-02 trial: From Bench to Bedside and Beyond—Implementing a Hospital-Based CAR T Program and Integrating It into the Spanish NHS” with Dr. Valentín Ortiz-Maldonado. “Dear friends and colleagues, […]

AI Summary: Bereaved relatives delivered searing final testimonies as the Covid inquiry wound up four years of public hearings, recounting loved ones who died alone and demanding answers. Chair Baroness Heather Hallett defended the process and its roughly £200 million price tag as necessary to finish the work, despite public frustration and political scrutiny.

Moderna to Pay Up to $2.25B to Settle Patent Suit Over Covid-19 Vaccine Technology

Frank Vinluan / medcitynews - Under the settlement, Genevant Sciences and Arbutus Biopharma will grant Moderna a non-exclusive license to their lipid nanoparticle technology for mRNA delivery in infectious disease vaccines. If Moderna’s full financial payout to the companies is reache…

AI Summary: Moderna has agreed to settle long-running patent disputes over its COVID-19 vaccine technology for up to $2.25 billion, resolving litigation with several claimants. The deal provides Moderna with broad licensing rights and clears a major legal uncertainty, allowing the company to move forward without another courtroom cliffhanger.